Who is sponsoring NCT04635735?

NCT04635735 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT04635735?

Interventions in NCT04635735: Ipilimumab.

What condition does NCT04635735 study?

NCT04635735 studies Relapsed/Refractory Multiple Myeloma.

Is NCT04635735 still recruiting?

NCT04635735 is currently terminated. Last updated 23 March 2023.

Are results published for NCT04635735?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-03-23 · How we verify

NCT04635735

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Terminated Phase 1, PHASE2 Results posted Last updated 23 March 2023

What this trial tests

Phase 1, PHASE2 trial testing Ipilimumab in Relapsed/Refractory Multiple Myeloma in 3 participants. Terminated before completion.

Timeline

12 January 2020

Primary endpoint
2 February 2023

2 February 2023

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	12 January 2020
Primary completion	2 February 2023
Estimated completion	2 February 2023
Sites	7 locations across United States

Drugs / interventions tested

Ipilimumab — full drug profile →

Conditions studied

Relapsed/Refractory Multiple Myeloma — all drugs for Relapsed/Refractory Multiple Myeloma →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

Adults 21 to 73, any sex, with Relapsed/Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Checkpoint inhibition in hematologic malignancies.
Tsumura A, Levis D, Tuscano JM. · · 2023 · cited 14× · PMID 37920162 · DOI 10.3389/fonc.2023.1288172

Verify or expand the search:

Other trials of Ipilimumab

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07128680 — Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Met · Phase 1 · recruiting

Other recruiting trials for Relapsed/Refractory Multiple Myeloma

Currently open trials in the same condition.

NCT07493135 — A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
NCT07509086 — IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia · Phase 2 · recruiting
NCT06730256 — A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting
NCT06669247 — A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants · Phase 1, PHASE2 · recruiting
NCT06718270 — a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia · EARLY_PHASE1 · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04635735 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 23 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04635735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing